Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Core Insights - Alterity Therapeutics has announced the completion of the last patient visit in the ATH434-201 Phase 2 trial for early-stage Multiple System Atrophy (MSA), with topline data expected in early 2025 [1][2] Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly targeting MSA and other Parkinsonian disorders [1][6] - The lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins associated with neurodegeneration, showing promise in preclinical studies [4][6] Clinical Trial Details - The ATH434-201 Phase 2 trial is a randomized, double-blind, placebo-controlled study involving 77 adults, assessing the efficacy and safety of ATH434 over a 12-month treatment period [3][4] - The trial aims to evaluate neuroimaging and protein biomarkers, including brain iron and α-synuclein, to demonstrate drug activity and clinical efficacy [3][4] Disease Context - Multiple System Atrophy (MSA) is a rare neurodegenerative disease characterized by autonomic nervous system failure and impaired movement, affecting at least 15,000 individuals in the U.S. [5][6] - Currently, there are no approved drugs that can slow the progression of MSA, highlighting the potential significance of ATH434 as a treatment option [5][6]